Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A...

Area of Science:

• Immunology
• Rheumatology
• Clinical Trials

Background:

• Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
• Rituximab is a standard treatment for other ANCA-associated vasculitides, but its efficacy in EGPA requires further investigation.

Purpose of the Study:

• To compare the efficacy of rituximab versus conventional strategies for inducing remission in patients with EGPA.
• To evaluate secondary endpoints including remission duration, glucocorticoid dosage, and safety.

Main Methods:

• A Phase 3, multicenter, randomized, double-blind, controlled superiority trial involving 105 EGPA patients with active disease.
• Participants received either glucocorticoids plus rituximab or a conventional strategy (glucocorticoids alone or with cyclophosphamide).
• Remission was defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 and prednisone dose ≤7.5 mg/d at day 180.

Main Results:

• No statistically significant difference in remission rates was observed between the rituximab group (63.5%) and the conventional strategy group (60.4%) at day 180 (P=0.75).
• Remission duration, relapse rates, average daily glucocorticoid dose, and adverse event rates were similar between the two groups.
• The study design was not suitable for determining equivalence between rituximab and cyclophosphamide in severe EGPA.

Conclusions:

• Rituximab did not demonstrate superiority over conventional remission induction strategies in EGPA patients.
• Further research may be needed to explore rituximab's role in specific EGPA subgroups or for long-term maintenance therapy.